NeuroTrauma Sciences Presents Update on Neuroprotective Compounds NTS-104 and NTS-105 at the 12th Annual Traumatic Brain Injury Conference

07 Jun 2022
www.prnewswire.com
Small molecular drug
ATLANTA, June 7, 2022 /PRNewswire/ -- NeuroTrauma Sciences, LLC (NTS), a private biopharmaceutical company developing a portfolio of disease-modifying therapeutic candidates to treat the devastating effects of traumatic brain injury (TBI), today provided an update on the development of its lead drug candidates NTS-104 and NTS-105 in traumatic brain injury. Tom J. Parry, Ph.D., MBA, Chief Science Officer, presented recent results during an oral session at the 12th Annual Traumatic Brain Injury Conference held in Washington, DC.
In this presentation, Dr. Parry discussed recent advances in the development of novel neurosteroids for the treatment of TBI, including preclinical data for its novel neuroactive small molecules NTS-104 and NTS-105, which NeuroTrauma Sciences is developing for acute, subacute and chronic brain injury treatment. The presentation is available on the NTS website, www.neurotraumasciences.com.
Highlights of Dr. Parry's oral presentation:
NTS-104 is a novel, water-soluble prodrug that converts rapidly to NTS-105 in plasma
NTS-105 is a novel, potent neurosteroid that crosses the blood-brain barrier
NTS-105 has nanomolar affinity for PR nuclear hormone receptors
Administration of NTS-104 following TBI or stroke in rats improves functional outcomes and lesion volume
NTS-104 administration reduces acute inflammatory mediators and inflamed cerebrovascular endothelial cell markers
Efficacy has been demonstrated in multiple independent laboratories and models
NTS-104 is expected to enter Phase 1 clinical trials in Q4 2022
NTS-104 has an issued composition-of-matter patent; NTS-104 and NTS-105 have issued method of use patents
"Traumatic brain injuries elicit complex pathologies and represent a major cause of death and disability," said Dr. Parry. "Preclinical data for NTS-104 and NTS-105 demonstrate improved functional outcomes in TBI and offer promise for the treatment of these pathologies."
About NTS-104 / NTS-105
NTS-104 is a novel molecule that has demonstrated efficacy in preclinical models of ischemic stroke and acute TBI. NTS-104, a soluble prodrug, is readily delivered to the bloodstream where it is converted to the active neurosteroid NTS-105. NTS-105 rapidly enters the brain at concentrations sufficient to modulate key target receptors, protecting neurons from inflammation, ischemia and programmed cell death.
NeuroTrauma Sciences (NTS) is a biopharmaceutical company advancing its mission to address the range of deficits caused by stroke and traumatic brain injury. These remain areas of high unmet need for millions of patients worldwide who have limited therapeutic options to alleviate the cognitive, functional, and neurobehavioral effects resulting from these insults. By following the science and leveraging our insights into the pathophysiology of the injured brain, NTS is advancing a pipeline of candidates targeting acute, subacute and chronic stroke and TBI. For additional information, please visit www.neurotraumasciences.com.
Contacts:
SMP Communications
Susan Pietropaolo
201-923-2049
[email protected]
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.